Assuming you actually did buy, it's stupid to put your life savings into any one stock, much less a small, cash flow negative, risky one like this.
It's also stupid not to Google a word you don't understand.
Last, XON is a long term bet and has an excellent chance to pay off handsomely if you just wait long enough. Kirk has a splendid record and XON is quite diversified.
So...My sincere advice is to buy an S&P 500 index fund like Vangard's.
You should NOT be speculating in the stock market.
We can't compete on a cost basis with sprays and they know it. Our tech will be for wealthier communities.
I'll bet we could combine the oxitec tech with the Wolbachia bacteria and increase it's effectiveness and safety considerably!
Loud Bronx cheer to you!
In house technology is neither old nor useless.
Questions remain...of course, this is cutting edge science and science research is all about questions.
I signed up for the MF stock service and bought some of their strong recommendations, including Gopro,, CMG, Illumine, Fire eye and a couple of others...Complete disaster. They have become what they used to ridicule mercilessly.
but we've done so little with the IP we already have had for years that i can't get too excited about it...
Waaaay more promises than action.
Our initial patents were extremely promising and we diddled around till the patents ran out and someone else took it across the goal line.
We are now only contemplating beginning a Ph 3 trial when we should have advanced multiple constructs well into Ph3 and beyond years ago.
I'm pretty exhausted and getting old waiting.
That's admirable and well worth funding.
But we should be focusing on pushing our most promising constructs aggressively through clinical trials. And much less on promotional presentations and posturing as well as administration.
Our prior CEO was much worse.
A ruthlessly efficient scientist/businessman as CEO
would make all the difference.
The neo epitope approach seems rather indiscriminate. Do we want to bother the immune system about harmless small mutations that are in the mix?
Of course, we are not the only company delving into this area.
The one big company with the greatest breast onco-gene data base regards that info as proprietary, takes biopsy samples and runs very limited sequencing on it and returns very vague and non specific, but costly reports we found.
So it'd be great if these new results were added to the common pool of knowledge.
My bet is that epigenetic changes will prove extremely important in all cancers.
Does anyone know if the neo-epitope approach includes epigenetic results?
It doesn't matter...your investment will have the same $ value either way.
All the excitement is just day trader hysteria.
Be real pleased to take advantage of that!
The other small bios i'm in are still dreaming of having a drug ready for market.
Their risk level makes this seem staid.
Fair chance it'll sink some more as the disloyal day traders bail out..Then we can #$%$ up some more.